U.S. private equity firm Paine Schwartz Partners is considering selling a stake in Verdesian Life Sciences to capitalize on rising demand for crop-health assets, according to Bloomberg, citing people with knowledge of the matter. A deal could value Verdesian at more than $500 million, according to the sources.
Transparency Across the Fertilizer Value-Chain